RELVAR

RELVAR ELLIPTA 184/22MCG – Relvar Ellipta is indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate:

• patients not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short acting beta2-agonists.

• patients already adequately controlled on both inhaled corticosteroid and long-acting beta2-agonist.